Wockhardt surges on initiating global Phase III clinical study of WCK 5222

Wockhardt is currently trading at Rs. 234.40, up by 3.40 points or 1.47% from its previous closing of Rs. 231.00 on the BSE.

The scrip opened at Rs. 234.90 and has touched a high and low of Rs. 236.20 and Rs. 231.85 respectively. So far 17787 shares were traded on the counter.


The BSE group ‘A’ stock of face value Rs. 5 has touched a 52 week high of Rs. 492.05 on 08-Oct-2021 and a 52 week low of Rs. 201.55 on 06-Jul-2022.

Last one week high and low of the scrip stood at Rs. 242.00 and Rs. 227.20 respectively. The current market cap of the company is Rs. 3373.17 crore.

The promoters holding in the company stood at 65.75%, while Institutions and Non-Institutions held 2.91% and 31.34% respectively.

Wockhardt has initiated global Phase III clinical study of its new antibiotic candidate WCK 5222. The company has completed the first site initiation visit for the study.

This is double-blind, multi-center, efficacy, safety, and tolerability study in the treatment of hospitalized adults with Complicated Urinary Tract Infections, including Acute Pyelonephritis.

This Study will have 70 centres worldwide in 11 countries including US, Europe, India, China and Latin America. This global study is expected to be completed in 18 months.

Wockhardt is a research based global pharmaceutical and Biotech Company headquartered in Mumbai, India.